Contrast agent iopromide injection

A total of 60 New Zealand rabbits were used for all experiments. The animals were obtained from the Beijing huafukang Biotechnology Co., Ltd. and kept in a cage with access to food and water ad libitum (12 h light/dark cycle) at 25 ± 2°C and 45–50% humidity. 60 New Zealand rabbits (Bodyweight: 2.0–3.0 kg, male or female) were randomly divided into four groups, with 15 rabbits in each group. Group A (control group): intravenous injection of normal saline (24 ml/kg, from Shanghai Baite Pharmaceutical Co., Ltd, China); Group B (contrast group): intravenous injection of contrast agent iopromide injection (24 ml/kg, from Bayer healthcare Co., Ltd, Germany); Group C (hydration group): Intravenous injection of the contrast agent iopromide injection (24 ml/kg) and intravenous injection of normal saline (24 ml/kg); Group D (nano liposome group): Intravenous injection of contrast agent iopromide injection (24 ml/kg) and infusion of nano liposomes (2 ml/kg, Shanghai Shunna Technology Co., Ltd., China). We performed the following experiments on all rabbits after 4 weeks of treatment. Animal protocols adopted in the present study were approved by the medical ethics committee of Tianjin Chest Hospital (Approval No. 2020 YS-047-01), which follows the guidelines established by the United States National Institutes of Health.